NCT04061655View on ClinicalTrials.gov

Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

January 6, 2020

Study Completion Date

January 10, 2020

Conditions
Complications
Interventions
DRUG

Iron Isomaltoside 1000

Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.

OTHER

placebo

Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.

Trial Locations (1)

11566

Ain Shams university, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT04061655 - Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion | Biotech Hunter | Biotech Hunter